ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Precision mRNA Delivery via Ultrasound-Controlled Release Perfluorocarbon Emulsions: An Innovative Ultrasound Theranostic Strategy with
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Messenger RNA (mRNA) therapeutics provide promising opportunities in cardiovascular diseases. However, effective vascular mRNA delivery requires precise delivery, controlled release, and efficient transfection. To address these challenges, the study utilizes phase-change perfluorocarbon nanodroplets (PFC NDs) as a unique theranostic platform, integrating multimodal imaging with ultrasound-triggered mRNA release for enhanced vascular transfection. Lipid-coated PFC NDs are engineered using perfluoro-crown-ether (PFCE), perfluorohexane (PFH), and perfluoropentane (PFP) as core materials. These nanodroplets (200-300 nm) are optimized for mRNA loading and cellular uptake, exhibiting strong ultrasound contrast in tissue-mimicking phantoms and in vivo. Each PFC generated distinct fluorine-19 magnetic resonance imaging signals, allowing tri-spectral imaging capabilities. In vitro, PFH and PFP NDs increased enhanced green fluorescent protein mRNA transfection in CHO cells (p < 0.0001), with ultrasound stimulation further improving efficiency compared to unstimulated controls (p < 0.05). In vivo ultrasound-guided activation of PFH NDs resulted in higher mCherry protein expression in murine carotid arteries (p < 0.05), demonstrating site-specific gene therapy. This study establishes PFH NDs as an advanced theranostic platform for vascular mRNA delivery, integrating diagnostics and therapeutics into a single system. By leveraging ultrasound-responsive activation, these nanodroplets overcome existing delivery limitations, offering a new avenue for precision medicine in cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.